Skip to main content
Equibles
NRIX logo

NRIX · Nurix Therapeutics, Inc.

Track NRIX — free

Use NRIX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about NRIX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$26.95 +0.68 (+2.59%) At close · Aug 25
Market Cap
$2.75B
Shares
103.78M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-06-23 BTK A428D is a recurrent, pan-resistance mutation in patients with acquired resistance to BTK degraders Event
2026-06-08 Earnings conference call (announced in 8-K) Earnings call
2026-06-08 Unlocking the Full Potential of Bexobrutideg Event
2026-06-03 Jefferies Global Healthcare Conference Conference
2026-05-20 2026 RBC Capital Markets Global Healthcare Conference Conference
2026-05-15 2026 Annual Meeting of Stockholders Shareholder meeting
2026-05-14 BTK degradation by bexobrutideg suppresses B cell activation and FcεRI-mediated degranulation in preclinical models of chronic spontaneous urticaria Event
2026-04-21 Discovery and Characterization of CBL-B Intramolecular Glue Inhibitors That Increase T Cell Activation and Suppress Tumor Growth Event
2026-04-20 NRX-4972, a selective, oral, Aurora kinase A degrader, demonstrates increased efficacy in an SCLC tumor model, and greater in vitro synergy than an AURKA inhibitor Event
2026-04-20 NRX-0305 is an Orally Bioavailable, Pan-Mutant BRAF Degrader that Exhibits Single Agent and Combination Efficacy with MEKi or anti-EGFR Across Class 1/2/3 BRAF Mutant Cancers Event
2026-04-20 NRX-0305: an Orally Bioavailable, CNS Penetrant, Pan-Mutant BRAF Degrader Demonstrates Robust Efficacy in Intracranial Models of Melanoma Brain Metastasis and Primary Glioma Event
2026-04-13 25th Annual Needham Virtual Healthcare Conference Conference
2026-03-24 Combinatorial Optimization of Degrader-Antibody Conjugates Enabled by Automation Event
2026-01-12 44th Annual J.P. Morgan Healthcare Conference Conference
2025-12-08 Webcast to Discuss Data Presented at 67th American Society of Hematology (ASH) Annual Meeting Shareholder meeting
2025-12-08 Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in Patients with Waldenström Macroglobulinemia: Updated Results from an Ongoing Phase 1a/b Study Event
2025-12-06 Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation Event
2025-12-06 Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial Event
2025-12-03 Piper Sandler 37th Annual Healthcare Conference Conference
2025-11-18 Jefferies Global Healthcare Conference in London Conference
2025-11-13 Stifel 2025 Healthcare Conference Conference

Source: https://www.nurixtx.com/resource-library/

Key facts CIK 1549595 CUSIP 67080M103 13F (30d) 196 filings 190 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)